Kick-starting the cancer-immunity cycle by targeting CD40

Peter Ellmark; S. M. Mangsbo; C. Furebring; T. H. Totterman; P. Norlen

doi:10.1080/2162402X.2015.1011484

Kick-starting the cancer-immunity cycle by targeting CD40

Peter Ellmark, S. M. Mangsbo, C. Furebring, T. H. Totterman, P. Norlen

Institutionen för immunteknologi

Alligator Bioscience AB

Forskningsoutput: Tidskriftsbidrag › Debate/Note/Editorial

Sammanfattning

Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.

Originalspråk	engelska
Sidor (från-till)	e1011484
Tidskrift	OncoImmunology
Volym	4
Nummer	7
DOI	https://doi.org/10.1080/2162402X.2015.1011484
Status	Published - 2015

Ämnesklassifikation (UKÄ)

Immunologi inom det medicinska området

Tillgång till dokument

10.1080/2162402X.2015.1011484

Citera det här

@article{d878c92b517a44d092207543c0873d02,

title = "Kick-starting the cancer-immunity cycle by targeting CD40",

abstract = "Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.",

keywords = "CD40, PD-1, agonistic antibody, immunooncology",

author = "Peter Ellmark and Mangsbo, {S. M.} and C. Furebring and Totterman, {T. H.} and P. Norlen",

year = "2015",

doi = "10.1080/2162402X.2015.1011484",

language = "English",

volume = "4",

pages = "e1011484",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "7",

}

TY - JOUR

T1 - Kick-starting the cancer-immunity cycle by targeting CD40

AU - Ellmark, Peter

AU - Mangsbo, S. M.

AU - Furebring, C.

AU - Totterman, T. H.

AU - Norlen, P.

PY - 2015

Y1 - 2015

N2 - Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.

AB - Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.

KW - CD40

KW - PD-1

KW - agonistic antibody

KW - immunooncology

U2 - 10.1080/2162402X.2015.1011484

DO - 10.1080/2162402X.2015.1011484

M3 - Debate/Note/Editorial

C2 - 26140231

SN - 2162-4011

VL - 4

SP - e1011484

JO - OncoImmunology

JF - OncoImmunology

IS - 7

ER -

Kick-starting the cancer-immunity cycle by targeting CD40

Sammanfattning

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Fingeravtryck

Citera det här